# Recall Issued on Multiple Adult-Use Cannabis Products Tested by Keystone > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/keystone-laboratory-cannabis-recall-adult-use-products/ > **Published:** 2026-02-27T19:45:46-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T12:01:35-04:00 > **Clinical Summary:** Keystone Laboratory cannabis recall affects multiple adult-use products in New York. Verify product safety and avoid recalled cannabis items today. --- ✦ New CED Clinical Relevance#45[Clinical Context](https://cedclinic.com/cannabis-hyperemesis-syndrome-treatment-insights-2026/)Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. PolicySafetyIndustry Why This MattersRecalls of cannabis products distributed through licensed dispensaries signal potential contamination or quality failures that could expose patients to harmful substances, necessitating clinician awareness to counsel patients on product verification and safe purchasing practices. Healthcare providers should familiarize themselves with recall mechanisms in regulated cannabis markets to appropriately advise patients who use cannabis therapeutically or recreationally about verification procedures and risk mitigation. Understanding the prevalence and causes of cannabis product recalls in your jurisdiction enables informed patient counseling regarding potential health risks and the importance of sourcing products only from compliant dispensaries with verified testing results. Clinical Summary Multiple cannabis products tested by Keystone Laboratory have been subject to recall by New York State regulators due to testing integrity concerns and potential non-compliance with state safety standards. Product recalls in regulated cannabis markets typically stem from identification of contaminants including pesticides, heavy metals, and microbial agents, as well as inaccurate potency labeling that exceeds state-mandated thresholds. When testing facility results are questioned or products fail to meet regulatory compliance standards, state regulators mandate removal from dispensary shelves to protect public safety. Patients and consumers should verify with their licensed dispensary that recently purchased or planned cannabis purchases have not been included in current recall notices. Clinicians should be aware of these recalls when counseling patients on [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/), as products obtained prior to recall implementation may pose unquantified contamination risks. Patients obtaining cannabis from regulated dispensaries should actively cross-reference their purchases against official state recall lists to ensure product safety and accurate potency labeling. Dr. Caplan’s Take“I’ve seen recalls in regulated markets catch genuine contamination issues, but they also sometimes reflect testing inconsistencies and laboratory variation that doesn’t necessarily indicate consumer harm. Patients should absolutely verify their products against recall lists, but they also shouldn’t assume every flagged item poses clinical risk without understanding what specific contaminant was identified and at what level.” Clinical Perspective Healthcare providers should be aware that a recall affecting multiple adult-use cannabis products tested by Keystone has been issued in New York, which may impact patient access and product safety considerations in clinical discussions. While regulated cannabis markets employ testing protocols to identify contaminants and ensure [consumer safety](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/), recalls can occur due to laboratory findings, and patients may not always be aware of or check recall status before purchase or use. Providers should recognize that some patients may unknowingly possess recalled products, and the clinical relevance depends on the specific contaminant identified, the product type, frequency of use, and individual patient risk factors, though documentation of such recalls in the medical record may become important for liability and clinical decision-making purposes. When counseling patients about cannabis use, clinicians should encourage verification of product safety status with dispensaries and recommend checking official New York cannabis office recall lists, as this simple step can prevent exposure to potentially contaminated products and demonstrates a proactive approach 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+The+Office+Is+Issuing+A+Recall+On+Multiple+Adult-Use+Cannabis+Products+Tested+By+Keystone+%26%238230%3B+%40drcaplan&url=https%3A%2F%2Fharlemworldmagazine.com%2Fthe-office-is-issuing-a-recall-on-multiple-adult-use-cannabis-products-tested-by-keystone-state-testing-ny)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fharlemworldmagazine.com%2Fthe-office-is-issuing-a-recall-on-multiple-adult-use-cannabis-products-tested-by-keystone-state-testing-ny)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+The+Office+Is+Issuing+A+Recall+On+Multiple+Adult-Use+Cannabis+Products+Tested+By+Keystone+%26%238230%3B+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fharlemworldmagazine.com%2Fthe-office-is-issuing-a-recall-on-multiple-adult-use-cannabis-products-tested-by-keystone-state-testing-ny)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://harlemworldmagazine.com/the-office-is-issuing-a-recall-on-multiple-adult-use-cannabis-products-tested-by-keystone-state-testing-ny](https://harlemworldmagazine.com/the-office-is-issuing-a-recall-on-multiple-adult-use-cannabis-products-tested-by-keystone-state-testing-ny) Further Reading CED Clinic Blog[5 Transformative Effects of Cannabis Rescheduling: Medical Insight](https://cedclinic.com/cannabis-rescheduling/) Evidence Watch[`Cannabinoid Clinical Trials: CBD Cortical Excitability Study`](https://cedclinic.com/cannabidiol-lacks-intrinsic-anti-epileptic-properties-trial/) Cannabis Policy Wire[Policy Watch: 20 Regulatory Updates — March 10, 2026](https://cedclinic.com/dea-scheduling-synthetic-opioids-regulatory-updates-2026/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [OCM issues precautionary recall for select cannabis products tested by Keystone Lab – CBS 6 Albany](https://cedclinic.com/precautionary-cannabis-recall-keystone-lab-products/) Learn about the recent precautionary recall issued by the Office of Cannabis Management for cannabis products tested by Keystone Lab, highlighting safety concerns. [Read More](https://cedclinic.com/precautionary-cannabis-recall-keystone-lab-products/) [Ohio cannabis recall issued after product failed to meet testing requirements](https://cedclinic.com/cbd-gummies-ohio-practical-guide-health-conscious-users/) Explore how Ohio regulators responded to cannabis products failing safety and testing standards, emphasizing the importance of compliance. [Learn More](https://cedclinic.com/cbd-gummies-ohio-practical-guide-health-conscious-users/) [Missouri attorney general warns of unsafe, mislabeled cannabis products | ksdk.com](https://cedclinic.com/missouri-cannabis-product-safety-warning/) Missouri's attorney general highlights risks associated with mislabeled and unsafe cannabis products, underscoring the need for regulatory vigilance. [Discover More](https://cedclinic.com/missouri-cannabis-product-safety-warning/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).